sana.com (SANA): Prakiraan wutah bathi resik saben saham kanggo taun ngarep

Sana Biotechnology (SANA) maintains a high reputation in genetics due to its hypoimmune solutions, although it faces a fierce struggle to create universal cells. The projected net income per share growth rate reflects expert expectations, where the 2.10 mark serves as a key metric. While the team is deeply competent in science, high R&D costs necessitate strict financial control.

Sana Corp (SANA): Prakiraan wutah bathi resik saben saham kanggo taun ngarep saka 04.07.2022 nganti 15.11.2026

Ringkesan rincian data analitis Sana Biotechnology, Inc. (SANA)

- rega saham lan konsensus proyeksi valuasi:

Rega saham Sana Biotechnology Inc|SANA - Rata-rata rega prakiraan

- data kapitalisasi bursa:

Nilai pasar Sana Biotechnology Inc|SANA - Nilai Total Perusahaan

- rincian nilai buku perusahaan:

Aset Bersih saben Siji Saham Sana Biotechnology|SANA - Nilai Buku Perusahaan|Rasio Kapitalisasi marang Aset Bersih sana.com|SANA - Nilai Agregat Aset

- informasi babagan utang lan solvabilitas:

Total Utang marang Modal Sana Biotechnology|SANA - Tanggungan utang jangka dawa marang ekuitas|Utang jangka cendhak marang modal sana.com|SANA - Utang kumulatif perusahaan|Rasio utang marang kapitalisasi buku Sana Corp|SANA - Tanggungan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Sana Biotechnology|Indikator likuiditas cepet sana.com

- data bathi resik lan rasio valuasi:

SANA - Bathi pungkasan|Bathi mangsa ngarep Sana Biotechnology|SANA - Rasio rega pasar marang bathi resik|Pangali Forward P/E Sana Biotechnology, Inc.|SANA - Koefisien bali modal nimbang wutah|Pangali EV/EBITDA Sana Biotechnology|SANA - Bathi sadurunge bunga, pajak, lan amortisasi|Bathi saben saham sajrone rolas wulan pungkasan Sana Biotechnology|SANA - Bathi saben saham sajroning taun lumaku|Wutah bathi EPS kuartalan sana.com|SANA - Wutah bathi ing taun lumaku|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Sana Biotechnology

- statistik dodolan lan pendapatan perusahaan:

SANA - Pendapatan tahunan perusahaan|Volume dodolan mangsa ngarep perusahaan Sana Biotechnology Inc|SANA - Rega marang dodolan|Rasio rega marang prakiraan pendapatan Sana Corp|SANA - Wutah pendapatan taunan sajrone rolas wulan kepungkur

Analisis fundamental perusahaan:SANA, Sana Biotechnology, Inc.

To select assets with a high margin of safety, analyzing the dynamics of expected net profit is critical, as it measures the consensus estimate of future returns and filters out short-term market noise. The stability of the consensus earnings per share (EPS) forecast reflects market confidence in the success of Sana Biotechnology (SANA) cell modification platform clinical trials, where any sharp fluctuations signal risks in patient base formation.

Perusahaan pesaing